On Apr 7, Zacks Investment Research downgraded Natus Medical Inc BABY – a provider of newborn care and neurology healthcare products – to a Zacks Rank #5 (Strong Sell).Why the Downgrade?The downgrade primarily reflects lackluster preliminary first-quarter 2016 results. The company now estimates revenues at approximately $87.5 million, which is below the previously guided range of $96.5 million to $97.5 million.Natus Medical is scheduled to report its results on Apr 20. The dismal revenue performance is sure to hurt the bottom line, which is forecasted within the range of 34-35 cents. The Zacks Consensus Estimate for the same is currently pegged at 30 cents.We note that the first-quarter miss will also drag down full-year 2016 estimates. Management had expected full-year 2016 adjusted earnings in the band of $1.84–$1.88 per share, while revenues were projected in the range of $445–$455 million.Owing to the disappointing first quarter preliminary result, analysts are reasonably apprehensive, as is evident from the downward estimate revisions. Over the last 7 days, the Zacks Consensus Estimate fell 1.7% (3 cents) to $1.70 per share for 2016 while the same for 2017 declined 2.6% (5 cents) to $1.90.Stocks to ConsiderWhile we choose to avoid Natus Medical at present, better-ranked stocks include Accuray ARAY, AngioDynamics ANGO and Globus Medical GMED. All the three stocks carry a Zacks Rank #2 (Buy).Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report ACCURAY INC (ARAY): Free Stock Analysis Report ANGIODYNAMICS (ANGO): Free Stock Analysis Report NATUS MEDICAL (BABY): Free Stock Analysis Report GLOBUS MEDICAL (GMED): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research